Angle PLC Cancer Research Manchester Institute Publication
December 15 2014 - 1:00AM
RNS Non-Regulatory
TIDMAGL
Angle PLC
15 December 2014
For immediate release 15 December 2014
ANGLE plc
("ANGLE" or "the Company")
CANCER RESEARCH UK MANCHESTER INSTITUTE PUBLICATION
ANGLE plc (AIM: AGL OTCQX: ANPCY), the specialist medtech
company, is pleased to announce that Cancer Research UK Manchester
Institute has published results from its work with the Parsortix
system.
Cancer Research UK Manchester Institute (CRUK MI), formerly
known as the Paterson Institute for Cancer Research, submitted a
poster presentation at the National Cancer Research Institute
(NCRI) conference held in November 2014. Following review, this has
now been released publicly under CRUK's branding and is available
on ANGLE's website via the following link
www.angleplc.com/the-parsortix-system/download-files/
Key points in the publication include:
-- The capture efficiency of the Parsortix system is comparable
to that of CellSearch when using spiked samples best suited for
their system(1) ;
-- The Parsortix system does not require the use of capture
antibodies so "it facilitates capture of circulating tumour cells
(CTCs) with weak cell marker expression or cells lacking the
targeted epitope e.g. mesenchymal cells";
-- The Parsortix system is "straight-forward to use with minimal user intervention";
-- CRUK MI's optimised protocol can reduce the number of white
blood cells captured by the Parsortix system to below 200 providing
a high level of sample purity and this is independent of the volume
of blood processed;
-- Output from the Parsortix system is of sufficient purity that
it provides "an ideal starting point for both single cell isolation
and batch molecular analysis". It does not need further processing
steps and thus offers a cost effective route to analysis.
Ged Brady, Deputy and Genomics Leader within the Clinical &
Experimental Pharmacology group at Cancer Research UK Manchester
Institute commented:
"We see great promise in the application of the Parsortix
technology for harvesting CTCs for molecular analysis to enable
personalised cancer care. We have now selected the Parsortix system
to undertake pilot studies in both colorectal cancer and pancreatic
cancer."
ANGLE's Founder and Chief Executive, Andrew Newland,
commented:
"We believe the published results from CRUK MI's work will be
very helpful in developing commercial relationships to get the
Parsortix system adopted in the marketplace."
(1) The CellSearch system is the only FDA approved circulating
tumour cell system. It is approved for CTC enumeration only, for a
limited number of cancers and not for CTC harvesting for analysis.
The CellSearch system captures cells based on their expression of
the cell surface marker EpCAM. The cultured cells used for the
spiking tests were selected to have a uniformly high EpCAM
expression in order to ensure the effectiveness of the CellSearch
system. In contrast, circulating tumour cells (CTCs) in patient
blood have varying expressions of EpCAM. Certain types of CTCs,
such as mesenchymal, have little or no EpCAM expression and certain
cancer types, such as ovarian cancer, have very low levels of EpCAM
expression.
For further information:
ANGLE plc 01483 685830
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Cenkos Securities
Stephen Keys, Dr Christopher Golden
(Nominated adviser)
Andy Roberts, Christian Hobart (Sales) 020 7397 8900
Buchanan
Mark Court, Sophie Cowles 020 7466 5000
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a specialist medtech company commercialising a
disruptive platform technology that can capture cells circulating
in blood, such as cancer cells, even when they are as rare in
number as one cell in one billion blood cells, and harvest the
cells for analysis.
ANGLE's cell separation technology is called the Parsortix
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
two granted US patents and three extensive families of patents
being progressed worldwide. The system is based on a microfluidic
device that captures cells based on a combination of their size and
compressibility. The Parsortix system is established with strong
positive evaluations from leading cancer research centres and is
working with these cancer centres to demonstrate key applications.
Parsortix has a CE Mark for Europe and FDA authorisation is in
process for the US.
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The increase in cancer to a 1 in 3 lifetime incidence is set to
drive a multi $billion clinical market. The Parsortix system is
designed to be compatible with existing major medtech analytical
platforms and to act as a companion diagnostic for major pharma in
helping to identify patients that will benefit from a particular
drug and then monitoring the drug's effectiveness.
Now that the Parsortix system has been developed, ANGLE is
focused on its commercialisation in the market.
ANGLE has established formal collaborations with world-class
cancer centres and is working with these cancer centres to
demonstrate key applications for its Parsortix non-invasive cancer
diagnostic system as a liquid biopsy. Details are available here
http://www.angleplc.com/the-company/collaborators/
As well as cancer, the Parsortix technology has the potential
for deployment with several other important cell types in the
future.
ANGLE began trading on the AIM market of the London Stock
Exchange in March 2004 under the ticker symbol AGL. For further
information please visit: www.angleplc.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRADMMMZVKKGDZG
Angle (LSE:AGL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Angle (LSE:AGL)
Historical Stock Chart
From Sep 2023 to Sep 2024